Successful Deployment of an Artificial Intelligence Solution for Primary Diagnosis of Breast Biopsies in Clinical Practice

Back

Breast cancer is the most common malignant disease in women and the leading cause of cancer death in over 100 countries. Artificial-Intelligence (AI) based diagnostic solutions can support pathologists and improve diagnostic accuracy and efficiency.

This study assessed an AI-based solution (Galen™ Breast, Ibex Medical Analytics) for breast biopsies primary diagnosis, which was previously validated, and its implementation within a digital pathology workflow in a hospital pathology laboratory setting.

 

Click here to download the study:

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

How is artificial intelligence rising to the challenge in breast cancer diagnosis?

How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News

The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics